Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia

Br J Haematol. 2019 Jan;184(2):288-290. doi: 10.1111/bjh.15070. Epub 2017 Dec 21.
No abstract available

Keywords: dexamethasone; eltrombopag; immune thrombocytopenia; rituximab.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Benzoates / administration & dosage*
  • Dexamethasone / administration & dosage*
  • Drug Therapy, Combination / methods
  • Female
  • Follow-Up Studies
  • Humans
  • Hydrazines / administration & dosage*
  • Male
  • Middle Aged
  • Purpura, Thrombocytopenic, Idiopathic / diagnosis
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Pyrazoles / administration & dosage*
  • Rituximab / administration & dosage*

Substances

  • Benzoates
  • Hydrazines
  • Pyrazoles
  • Rituximab
  • Dexamethasone
  • eltrombopag